NetworkNewsBreaks – Aviragen Therapeutics, Inc. (NASDAQ: AVIR) Shares Drop on Merger Agreement with Vaxart, Inc.
Shares of Aviragen Therapeutics (NASDAQ: AVIR) are down 13.24% after the company this morning said it has entered into a definitive merger agreement with Vaxart, Inc., a privately-held company focused on developing oral recombinant vaccines based on its proprietary delivery platform. The combined company created by the merger, Vaxart, Inc., will be focused on developing orally-delivered therapeutics and prophylactics to address various viral infections. “After a comprehensive review of strategic alternatives, we are delighted to announce this transaction with Vaxart, which will complement Aviragen’s focus on infectious diseases and position us to create both near and long-term value for our…







